(S)-N-((S)-1-(2-amino-2-oxoethylamino)-4-methyl-1-oxopentan-2-yl)-1-((4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-13-sec-butyl-16-(4-hydroxybenzyl)-10-isobutyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl)pyrrolidine-2-carboxamide

ID: ALA3245749

Chembl Id: CHEMBL3245749

PubChem CID: 90672300

Max Phase: Preclinical

Molecular Formula: C44H69N11O11S2

Molecular Weight: 992.24

Molecule Type: Protein

Names and Identifiers

Canonical SMILES:  CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC1=O

Standard InChI:  InChI=1S/C44H69N11O11S2/c1-7-24(6)36-43(65)52-29(16-23(4)5)39(61)50-31(18-34(46)57)40(62)53-32(21-68-67-20-27(45)37(59)49-30(41(63)54-36)17-25-10-12-26(56)13-11-25)44(66)55-14-8-9-33(55)42(64)51-28(15-22(2)3)38(60)48-19-35(47)58/h10-13,22-24,27-33,36,56H,7-9,14-21,45H2,1-6H3,(H2,46,57)(H2,47,58)(H,48,60)(H,49,59)(H,50,61)(H,51,64)(H,52,65)(H,53,62)(H,54,63)/t24-,27-,28-,29-,30-,31-,32-,33-,36-/m0/s1

Standard InChI Key:  LOVOTNWLCYEBDN-IQXIKMHESA-N

Alternative Forms

1. Parent:

   

   ALA3245749

   H-Cys(1)-Tyr-Ile-Leu-Asn-Cys(1)-Pro-Leu-Gly-NH2

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Protein

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 992.24

Molecular Weight (Monoisotopic): 991.4619

AlogP: -1.83

#Rotatable Bonds: 16

Polar Surface Area: 356.44

Molecular Species: NEUTRAL

HBA: 14

HBD: 11

#RO5 Violations: 3

HBA (Lipinski): 22

HBD (Lipinski): 14

#RO5 Violations (Lipinski): 3

CX Acidic pKa: 9.50

CX Basic pKa: 7.66

CX LogP: -2.58

CX LogD: -2.90

Aromatic Rings: 1

Heavy Atoms: 68

QED Weighted: 0.08

Np Likeness Score: 0.50

References

1. Hruby VJ, Deb KK, Yamamoto DM, Hadley ME, Chan WY..  (1979)  [1-Penicillamine,2-leucine]oxytocin. Synthesis and pharmacological and conformational studies of a potent peptide hormone inhibitor.,  22  (1): [PMID:423185] [10.1021/jm00187a002]

2. Smith CW, Botos CR, Skala G, Walter R..  (1977)  Conformation-activity studies of oxytocin. Effects of structural modifications at corner positions of the beta-turns on the uterotonic activity.,  20  (11): [PMID:915905] [10.1021/jm00221a018]

Source

Source(1):

• Scientific Literature